Literature DB >> 8058586

Pharmacogenetic aspects in the metabolism of psychotropic drugs: pharmacokinetic and clinical implications.

E Spina1, A P Caputi.   

Abstract

Mesh：

Substances：

Year:  1994        PMID： 8058586     DOI： 10.1016/1043-6618(94)80036-7

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN： 1043-6618            Impact factor:   7.658


× No keyword cloud information.
  4 in total

1.  Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study.

Authors:  E Spina; C Gitto; A Avenoso; G M Campo; A P Caputi; E Perucca
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

Review 2.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

3.  Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study.

Authors:  Wim J Tamminga; Johan Wemer; Berend Oosterhuis; Anthonius de Boer; Stan Vranckx; Ben F H Drenth; Rokus A de Zeeuw; Lou F M H de Leij; Jan H G Jonkman
Journal:  Eur J Clin Pharmacol       Date:  2003-03-18       Impact factor: 2.953

4.  The effect of carbamazepine on the 2-hydroxylation of desipramine.

Authors:  E Spina; A Avenoso; G M Campo; A P Caputi; E Perucca
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.